BioVaxys: Funding, Investors & Team (Oct 2026)
BioVaxys Technology Corp. is a biotechnology company based in British Columbia that focuses on developing vaccines for viral and oncology diseases, as well as immuno-diagnostics. The company is working on a SARS-CoV-2 vaccine using its unique viral protein technology, and is planning a clinical trial for a cell vaccine in combination with checkpoint inhibitors for ovarian cancer treatment. Additionally, BioVaxys is developing a diagnostic tool to assess T cell immune response to SARS-CoV-2. The company has patents related to its cancer vaccine and is in the process of securing patents for its Covid-19 vaccine and diagnostic technologies.
BioVaxys has raised $3.8M across 6 funding rounds on record, the most recent an undisclosed round of $40k announced in Apr 2025.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioVaxys Company Profile and Key Stats
Latest funding round on record: Apr 2025.
BioVaxys Funding Rounds
BioVaxys raised $1.2M in an undisclosed round announced in Jan 2024.
2 months later, an undisclosed round of $1.0M was announced in Mar 2024.
2 months later, an undisclosed round of $280k was announced in May 2024.
6 months later, an undisclosed round of $710k was announced in Nov 2024.
2 months later, an undisclosed round of $540k was announced in Jan 2025.
3 months later, an undisclosed round of $40k was announced in Apr 2025.
BioVaxys Founders and Leadership Team
No contact details are on record for this team yet.
BioVaxys Funding Compared to Other Biotechnology Startups
BioVaxys' latest round of $40k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioVaxys in Biotechnology and New York
Companies Similar to BioVaxys
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BioVaxys Funding FAQs
What does BioVaxys do?
BioVaxys Technology Corp. is a biotechnology company based in British Columbia that focuses on developing vaccines for viral and oncology diseases, as well as immuno-diagnostics. The company is working on a SARS-CoV-2 vaccine using its unique viral protein technology, and is planning a clinical trial for a cell vaccine in combination with checkpoint inhibitors for ovarian cancer treatment. Additionally, BioVaxys is developing a diagnostic tool to assess T cell immune response to SARS-CoV-2. The company has patents related to its cancer vaccine and is in the process of securing patents for its Covid-19 vaccine and diagnostic technologies.
How much funding has BioVaxys raised?
BioVaxys has raised $3.8M across 6 rounds on record. The most recent is an undisclosed round of $40k announced in Apr 2025.
When did BioVaxys last raise funding?
BioVaxys' most recent funding round on record is an undisclosed round of $40k, announced in Apr 2025.
Who founded BioVaxys?
FundedIQ lists David Berd (Founder) at BioVaxys.
Where is BioVaxys headquartered?
BioVaxys is based in New York, United States.
How many employees does BioVaxys have?
BioVaxys is in the 1-10 employee band.
How does BioVaxys' funding compare to other Biotechnology startups?
BioVaxys' latest round of $40k is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioVaxys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioVaxys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.